These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34880755)

  • 1. Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections.
    Wang P; Zhang Q; Feng M; Sun T; Yang J; Zhang X
    Front Pharmacol; 2021; 12():754844. PubMed ID: 34880755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.
    Miglis C; Rhodes NJ; Avedissian SN; Kubin CJ; Yin MT; Nelson BC; Pai MP; Scheetz MH
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
    Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
    Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
    Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
    Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant
    Yu Z; Liu X; Du X; Chen H; Zhao F; Zhou Z; Wang Y; Zheng Y; Bergen PJ; Li X; Sun R; Fang L; Li W; Fan Y; Wu H; Guo B; Li J; Yu Y; Zhang J
    Front Pharmacol; 2022; 13():975066. PubMed ID: 36588676
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.
    Bunnell KL; Pai MP; Sikka M; Bleasdale SC; Wenzler E; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
    Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K
    Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.
    Blackman AL; Jarugula P; Nicolau DP; Chui SH; Joshi M; Heil EL; Gopalakrishnan M
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients.
    Li Y; Deng Y; Zhu ZY; Liu YP; Xu P; Li X; Xie YL; Yao HC; Yang L; Zhang BK; Zhou YG
    Front Pharmacol; 2021; 12():727170. PubMed ID: 34512352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
    Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.